The University of Michigan Protein Assembly Lab Selects Hyperion Imaging System for Research In Cancer Immunotherapy and Immune Phenotyping

▤ Summary

SOUTH SAN FRANCISCO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that The University of Michigan Protein Assembly Lab, a hub for collaborative and innovative research at the intersection of synthetic biology, protein engineering and personalized medicine, has chosen the Hyperion™ Imaging System to expand its capabilities in multiparameter imaging and immune profiling of tissue. Building upon important research enabled by mass cytometry since 2016, the lab acquired a Hyperion Imaging System to expand its capabilities in multiparameter spatial analysis of the tissue microenvironment. “Our lab is exploring novel ways to push the field of precision health forward by engineering multiple protein assemblies into single entities that can act in an orchestrated and synergistic manner to carry out specific and sophisticated immunological functions to treat cancer and autoimmune disorders and to prevent viral infections,” said Wen. “We believe this approach could contribute to advances in a number of areas, including synthetic biology, cancer immunotherapy and immune phenotyping.” “The Hyperion Imaging System enables us to extract a wealth of useful information from limited patient biopsy samples, which is critical to understanding patient-to-patient variability and developing novel and precise diagnostic and therapeutic reagents,” Wen said. “We are truly excited that the University of Michigan Protein Assembly Lab has chosen the Hyperion Imaging System for critical research in a range of key areas including cancer immunotherapy and immune phenotyping,” said Chris Linthwaite, Fluidigm President and CEO.

▦ Linked Companies

Standard BioTools

$100M to $250M